Rheumatology Archives - Page 5 of 10 - Hospital Healthcare EuropeHospital Healthcare Europe

This website is intended for healthcare professionals only.

Rheumatology

Treating giant cell arteritis

Optimising management of systemic lupus erythematosus

Challenges in the management of psoriatic arthritis

Sobi launches new treatment for patients with rare inflammatory diseases

Sobi launches new treatment for patients with rare inflammatory diseases

New treatment for patients with rare inflammatory diseases

New treatment for patients with rare inflammatory diseases

Anakinra receives positive opinion from CHMP for the treatment of Still’s disease

Anakinra receives positive opinion from CHMP for the treatment of Still’s disease

A promising new drug to combat serious inflammatory disease

A promising new drug to combat serious inflammatory disease

Adalimumab biosimilar approved in Europe for the treatment of multiple chronic inflammatory diseases

Adalimumab biosimilar approved in Europe for the treatment of multiple chronic inflammatory diseases

First patient randomised in study evaluating safety and efficacy of anakinra in Still’s disease

First patient randomised in study evaluating safety and efficacy of anakinra in Still’s disease

Efficacy and safety maintained in patients who switched from Humira to biosimilar

Efficacy and safety maintained in patients who switched from Humira to biosimilar

Positive CHMP opinion for adalimumab biosimilar

Positive CHMP opinion for adalimumab biosimilar

Sarilumab approved for the treatment of moderately to severely active rheumatoid arthritis in adults

Sarilumab approved for the treatment of moderately to severely active rheumatoid arthritis in adults

Data support the efficacy and safety of biosimilar rituximab in autoimmune disease and oncology

Data support the efficacy and safety of biosimilar rituximab in autoimmune disease and oncology

Biosimilar adalimumab and infliximab accepted for regulatory review by the EMA

Biosimilar adalimumab and infliximab accepted for regulatory review by the EMA

Proposed rituximab and etanercept biosimilars recommended for approval in Europe

Proposed rituximab and etanercept biosimilars recommended for approval in Europe